Measure | Preimplementation (n=50) | Postimplementation (n=249) | P value | OR |
Primary outcomes | ||||
Time to switch* (median) | 15 hours 42 min | 4 hours 20 min | 0.0006 | NA |
No of eligible patients switched within 24 hours* | 32 (64%) | 203 (82%) | 0.006 | 2.48 (1.2–5) |
Secondary outcomes | ||||
Duration of intravenous therapy (median) | 62 hours 45 min | 48 hours | 0.01 | NA |
Length of hospital admission (median) | 78 hours | 63 hours 51 min | 0.008 | NA |
Intravenous line-associated complications | 0 (0%) | 3† (1%) | 0.44 | (Undefined) |
No of patients readmitted | 1 (2%) | 8 (3%) | 0.65 | 1.63 (0.21–73.62) |
No of patients recommenced intravenous medication | 2 (4%) | 3 (1%) | 0.16 | 0.29 (0.03–3.61) |
Bold values are statistically significant.
*Time and eligibility to switch from intravenous-to-oral medications after meeting guideline criteria for switch.
†One patient had extravasation injury and two patients had thrombophlebitis.
NA, not available.